Autopsy report · NCT06240364

Effects of AffronEye®/ Crocuvis+® on Dry Eye Syndrome

“Study withdrawn prior to enrollment due to sponsor decision”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

University of Alicante

Sponsor type

University, hospital or other

Conditions

Dry Eye Syndrome

Interventions

Saffron extract (Crocus sativus); Placebo

Participants

0

Sites

1

Countries

Spain

Trials that died the same way

• EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis
  “Study Withdrawn by Sponsor prior to Enrollment.” (93% match in meaning)
• Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
  “Study withdrawn by Sponsor” (90% match in meaning)
• A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy
  “Study was withdrawn per sponsor decision” (90% match in meaning)
• A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a
  “Sponsor decision to withdraw study at this time.” (85% match in meaning)
• Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial
  “Sponsor withdrew the study” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.